Insider Buying: OraSure Technologies (NASDAQ:OSUR) CEO Purchases $66,066.00 in Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) CEO Manner Carrie Eglinton purchased 22,022 shares of the stock in a transaction on Friday, March 13th. The shares were purchased at an average cost of $3.00 per share, for a total transaction of $66,066.00. Following the acquisition, the chief executive officer directly owned 2,158,574 shares of the company’s stock, valued at approximately $6,475,722. This represents a 1.03% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

OraSure Technologies Price Performance

Shares of NASDAQ OSUR opened at $2.90 on Thursday. The firm has a fifty day moving average price of $2.84 and a 200-day moving average price of $2.79. The stock has a market cap of $200.48 million, a PE ratio of -3.12 and a beta of 0.88. OraSure Technologies, Inc. has a 1 year low of $2.08 and a 1 year high of $4.22.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The firm had revenue of $26.76 million for the quarter, compared to the consensus estimate of $26.44 million. OraSure Technologies had a negative net margin of 59.76% and a negative return on equity of 16.45%. On average, research analysts expect that OraSure Technologies, Inc. will post -0.08 EPS for the current year.

Institutional Investors Weigh In On OraSure Technologies

Several institutional investors and hedge funds have recently modified their holdings of the stock. Kotler Kevin bought a new stake in shares of OraSure Technologies in the fourth quarter worth about $4,359,000. Altai Capital Management L.P. boosted its stake in OraSure Technologies by 73.4% during the third quarter. Altai Capital Management L.P. now owns 3,748,836 shares of the medical instruments supplier’s stock valued at $12,034,000 after buying an additional 1,586,488 shares during the last quarter. Private Management Group Inc. boosted its stake in OraSure Technologies by 23.6% during the second quarter. Private Management Group Inc. now owns 5,461,440 shares of the medical instruments supplier’s stock valued at $16,384,000 after buying an additional 1,044,213 shares during the last quarter. Millennium Management LLC grew its holdings in OraSure Technologies by 71.1% during the 3rd quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier’s stock valued at $6,781,000 after buying an additional 878,151 shares in the last quarter. Finally, Systematic Financial Management LP grew its holdings in OraSure Technologies by 35.3% during the 2nd quarter. Systematic Financial Management LP now owns 2,229,076 shares of the medical instruments supplier’s stock valued at $6,687,000 after buying an additional 581,926 shares in the last quarter. Institutional investors own 93.50% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d)” rating on shares of OraSure Technologies in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.